<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Palatino;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
.MsoChpDefault
	{font-family:"Calibri","sans-serif";}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>The hepatitis viruses are a group of five viruses (A
through E) that infect the liver. Apart from sharing the same host-cell type,
they have very little else in common, and belong to five distinct viral
families. These viruses vary significantly with regards to the duration and
severity of the infections that they cause. The five hepatitis viruses will now
be considered individually:</span></font></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><font size=2
face=Palatino><span style='font-size:10.0pt;line-height:115%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
size=2 face=Palatino><span style='font-size:11.0pt;line-height:115%;font-family:
Palatino;font-weight:bold'>Hepatitis A</span></font></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><b><font
size=2 face=Palatino><span style='font-size:10.0pt;line-height:115%;font-family:
Palatino;font-weight:bold'>&nbsp;</span></font></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><img
width=205 height=162 src="Virology_7-Hepatitis%20Viruses%23_image001.png"
align=left hspace=12
alt="Hepatitis A&#13;&#10;&#13;&#10;Family		Picornavirus&#13;&#10;&#13;&#10;Genome	(+)ssRNA&#13;&#10;&#13;&#10;Capsid		Icosahedral&#13;&#10;&#13;&#10;Envelope?	No&#13;&#10;"></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>Hepatitis A is an enterovirus belonging to the
family <i><span style='font-style:italic'>picornaviridae</span></i>. It
contains a (+)ssRNA genome, has icosahedral capsid symmetry, and is
non-enveloped. In parts of the world with low sanitation, a large portion of
the population is seropositive at a young age, and do not present with overt
disease. This is a result of passive-to-active immunity, where the individual
is first protected passively by maternal antibody, and then develops their own
immunity against the virus.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>In the United States and other parts of the world
where sanitation is high, this passive-to-active immunity often does not occur
during infancy, and overt disease can occur in adulthood. There have been
periodic Hepatitis A outbreaks in the United States in both the 20th and 21st
centuries, typically as a result of poor sanitation among food handlers. Very
rarely, this virus may be transferred from one individual to another via the
exchange of blood products during the viremic phase of the infection.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>The incubation period for Hepatitis A is roughly 30
days. However, individuals can excrete virions in their feces for several weeks
prior to exhibiting symptoms, thus explaining the potential for outbreaks. In
addition, viremia is often present for a week or so prior to the onset of
symptoms. </span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>Common signs of Hepatitis A include: nausea,
vomiting, fatigue, fever, loss of appetite, and most notably, jaundice.
Jaundice describes a generalized yellowing of the skin and sclera of the eyes
as a result of the incomplete degradation of heme to its excreted byproducts:
stercobilin, urobilin, and urobilogen. In addition, lab tests for patients with
acute Hepatitis A will often reveal elevated liver enzymes (ALT and AST) as a
result of viral damage to the liver, leading to the release of these enzymes
into circulation.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>There is a formaldehyde-killed vaccine available
against Hepatitis A. In addition, individuals who believe that they may have
been infected by the Hepatitis A virus, or who expect that they might encounter
it, may be given pooled human gamma globulin.<sup>6</sup> Despite the
administration of these antibodies, elevated liver function test suggests that
some liver damage is occurring in individuals who have been infected by the
virus. The pooled human gamma globulin provides the individual with protection
for four months, and the individual will become seropositive to the virus
following infection. This represents a type of artificial passive-to-active
immunity.</span></font></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><font size=2
face=Palatino><span style='font-size:10.0pt;line-height:115%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
size=2 face=Palatino><span style='font-size:11.0pt;line-height:115%;font-family:
Palatino;font-weight:bold'>Hepatitis B</span></font></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><b><font
size=2 face=Palatino><span style='font-size:10.0pt;line-height:115%;font-family:
Palatino;font-weight:bold'>&nbsp;</span></font></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><font size=2
face=Palatino><span style='font-size:10.0pt;line-height:115%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='margin-left:168.0pt;text-align:justify;line-height:
200%;text-autospace:none'><img width=205 height=170
src="Virology_7-Hepatitis%20Viruses%23_image002.png" align=left hspace=12
alt="Hepatitis B&#13;&#10;&#13;&#10;Family		Hepadnavirus&#13;&#10;&#13;&#10;Genome	dsDNA&#13;&#10;&#13;&#10;Capsid		Icosahedral&#13;&#10;&#13;&#10;Envelope?	Yes&#13;&#10;"><font
face=Palatino><span style='font-family:Palatino'>The Hepatitis B virus is a
hepadnavirus, and is one of a relatively few viruses that belong to Group VII
of the Baltimore classification system. It possesses an unusual genome
consisting of a single circular segment of DNA containing both double-stranded
and single-stranded regions. It has icosahedral symmetry, and is enveloped. In
addition to its genome, it also carries with it a “DNA polymerase,” which is
actually a reverse   transcriptase. </span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>Compared to Hepatitis A, this virus has a relatively
long incubation period of approximately 70 days. Early symptoms are similar to
those for hepatitis A, including nausea, vomiting, fever, loss of appetite or
jaundice. Approximately 95% of individuals infected with hepatitis B will clear
the infection, while the remaining 5% will go on to become chronic carriers. Of
this 5%, a portion will develop hepatocellular carcinoma as a result of the
infection.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>This virus is transmitted from person to person via
the transfer of blood products, sexual transmission, and perinatal infections.
In the past, transmission via transfusion was common, although this is no
longer true. Individuals who acquire the virus through the perinatal pathway
tend to have a worse prognosis than individuals who acquire it through one of
the other two pathways, and are more likely to develop chronic infection and
cancer of the liver. The risk of transmission via the perinatal route can be
diminished by the infusion of hepatitis B (HB)-immune globulin to the mother,
followed by vaccinating the infant shortly after birth.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>Blood tests are used to detect patients with active
Hepatitis B infections. Hepatitis B antigens “HB-Ags” are diagnostic, and
include HBsAg (a glycoprotein antigen), HBcAg (a nucleocapsid antigen), and
HBeAg (the antigen most commonly correlated with infections hepatitis B
antigens with progression to hepatic carcinoma). The damage caused by Hepatitis
B is due, in large part, to the cytotoxic arm of the adaptive immune system
(cytotoxic T-cells).</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>For patients who are believed to be infected with
hepatitis B, HB-immune globulin is an effective means of providing passive
immunity. For hepatitis A, pooled human gamma globulin is usually sufficient to
combat the disease. However, this typically does not provide sufficient
protection against hepatitis B, as antibody titers are typically too low.
HB-immune globulin is ideally administered within 24 hours of possible
exposure. There is a hepatitis B subunit vaccine available, which is
recommended for high-risk groups, such as health care providers.</span></font></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><font size=2
face=Palatino><span style='font-size:10.0pt;line-height:115%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal align=center style='text-align:center;line-height:200%;
text-autospace:none'><b><font size=2 face=Palatino><span style='font-size:11.0pt;
line-height:200%;font-family:Palatino;font-weight:bold'>Hepatitis C</span></font></b></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><img width=205 height=157
src="Virology_7-Hepatitis%20Viruses%23_image003.png" align=left hspace=12
alt="Hepatitis C&#13;&#10;&#13;&#10;Family		Flavivirus&#13;&#10;&#13;&#10;Genome	(+)ssRNA&#13;&#10;&#13;&#10;Capsid		Icosahedral&#13;&#10;&#13;&#10;Envelope?	Yes&#13;&#10;"><font
face=Palatino><span style='font-family:Palatino'>Hepatitis C is a flavivirus,
having a (+)ssRNA genome, icosahedral symmetry, and is enveloped. Much like
hepatitis B, it has a relatively long incubation period of approximately 70
days. Also like hepatitis B, much of the damage caused by the virus is a
function of the cytotoxic branch of cell-mediated immunity.<sup>  </sup>The
virus is most often transmitted via needle-sharing and sexual contact. The
symptoms of an acute hepatitis C infection are very similar to those of
hepatitis A and B.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>As with hepatitis B, hepatitis C can persist as a
chronic infection. While the percentage of individuals who develop a chronic
infection from hepatitis B is relatively low at approximately 5%, the number of
individuals who develop chronic hepatitis C is much higher, between 70 and 80%.
Individuals with a chronic infection are susceptible to cirrhosis and
hepatocellular carcinoma. It is estimated that the number of individuals with
chronic hepatitis C in the United States is approximately 4 million, which
represents greater than 1% of the entire population.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>The presence of hepatitis C is serum was originally
tested using an anti-HCV immunoassay. However, an alternative test that
utilizes PCR is a more sensitive alternative. There is no vaccine against
hepatitis C to date. Therapies include the administration of interferon-alpha
and ribavirin (an inhibitor of RNA synthesis). Recently, the FDA has approved
telaprevir and boceprevir, which are protease inhibitors. These two drugs, as
well as ribivirin, are used in conjunction with interferon.</span></font></p>

<p class=MsoNormal align=center style='text-align:center;line-height:200%;
text-autospace:none'><b><font size=2 face=Palatino><span style='font-size:11.0pt;
line-height:200%;font-family:Palatino;font-weight:bold'>Hepatitis D and E</span></font></b></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><img width=205 height=157
src="Virology_7-Hepatitis%20Viruses%23_image004.png" align=left hspace=12
alt="Hepatitis D&#13;&#10;&#13;&#10;Family		Deltavirus&#13;&#10;&#13;&#10;Genome	(-)ssRNA&#13;&#10;&#13;&#10;Capsid		Icosahedral&#13;&#10;&#13;&#10;Envelope?	Yes&#13;&#10;"><font
face=Palatino><span style='font-family:Palatino'>Hepatitis D is a deltavirus
possessing a (-)ssRNA genome, has icosahedral symmetry, and is enveloped. It
was previously known as the “delta agent.” Alone, the hepatitis D virus is
fairly innocuous. It lacks the genes necessary to form the surface
glycoproteins required for survival, and thus requires co-infection with the
hepatitis B virus, which can produce this envelope for it. Because of this,
immunity against hepatitis B may also provide immunity against hepatitis D.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>When the hepatitis D virus is able to replicate and
produce virions in the presence of hepatitis B, the infections are often very
severe and life-threatening. The mortality rate of hepatitis D infection is
greater than 20% when hepatitis B is also present.</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><img width=205 height=157
src="Virology_7-Hepatitis%20Viruses%23_image005.png" align=left hspace=12
alt="Hepatitis D&#13;&#10;&#13;&#10;Family		Hepevirus&#13;&#10;&#13;&#10;Genome	(+)ssRNA&#13;&#10;&#13;&#10;Capsid		Icosahedral&#13;&#10;&#13;&#10;Envelope?	No&#13;&#10;"><font
face=Palatino><span style='font-family:Palatino'>Much like hepatitis A,
hepatitis E is spread via the fecal-oral route. It is a member of the <i><span
style='font-style:italic'>hepevirus </span></i>family, possesses icosahedral
symmetry, and is non-enveloped. Infection typically results from contaminated
water or food, and is typically seen in developing countries. It has an
incubation of approximately 30 days, with a window between 15 and 60. </span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>Information pertaining to the hepatitis viruses is
available in the table below.</span></font></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>&nbsp;</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino;font-weight:bold'>Hepatitis A</span></font></b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino;font-weight:bold'>Hepatitis B</span></font></b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino;font-weight:bold'>Hepatitis C</span></font></b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino;font-weight:bold'>Hepatitis D</span></font></b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino;font-weight:bold'>Hepatitis E</span></font></b></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Family</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Picornavirus</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Hepadnavirus</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Flavivirus</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Deltavirus</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Hepevirus</span></font></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Genome</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>(+)ssRNA</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>dsDNA</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>(+)ssRNA</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>(-)ssRNA</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>(+)ssRNA</span></font></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Capsid</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Icosahedral</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Icosahedral</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Icosahedral</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Icosahedral</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Icosahedral</span></font></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Enveloped</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>No</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Yes</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Yes</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>Yes</span></font></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><font
  size=1 face=Palatino><span style='font-size:9.0pt;line-height:115%;
  font-family:Palatino'>No</span></font></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;text-autospace:
none'><font size=2 face=Palatino><span style='font-size:11.0pt;line-height:
200%;font-family:Palatino'>&nbsp;</span></font></p>

<p class=MsoNormal align=center style='text-align:center;line-height:200%;
text-autospace:none'><b><font size=2 face=Palatino><span style='font-size:11.0pt;
line-height:200%;font-family:Palatino;font-weight:bold'>References</span></font></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>3.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></font></span></font><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>Wheeler
CM, Robertson BH, Van Nest G, Dina D, Bradley DW, Field HA (1986). Structure of
the hepatitis A virion: peptide mapping of the capsid region. J Virol. 58(2):
307–313.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>4.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></font></span></font><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>Franco
E, Meleleo C, Serino L, Sorbara D, Zaratti L (2012). Hepatitis A: Epidemiology
and prevention in developing countries. </span></font><a
href="http://www.ncbi.nlm.nih.gov/pubmed/22489258"><font size=2 color=black
face=Times><span style='font-size:10.0pt;font-family:"Times","serif";
color:windowtext;text-decoration:none'>World J Hepatol.</span></font></a><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>
4(3):68-73.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>5.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></font></span></font><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>Bile
K, Aceti A, Hagi MA, Paparo BS, Pennica A, Celestino D, Sebastiani A (1986).
Primary hepatitis A virus infection in developing countries: decline of
maternal antibodies and time of infection. </span></font><a
href="http://www.ncbi.nlm.nih.gov/pubmed/3034305"><font size=2 color=black
face=Times><span style='font-size:10.0pt;font-family:"Times","serif";
color:windowtext;text-decoration:none'>Boll Ist Sieroter Milan.</span></font></a><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>
65(6):464-6.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>6.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></font></span></font><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>Chironna
M, Lopalco P, Prato R, Germinario C, Barbuti S, Quarto M (2004). “Outbreak of
Infection with Hepatitis A Virus (HAV) Associated with a Foodhandler and
Confirmed by Sequence Analysis Reveals a New HAV Genotype IB Variant.” J. Clin.
Microbiol. vol. 42 no. 6 2825-2828.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><b><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif";font-weight:bold'>7.<font
size=1 face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></font></span></font></b><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'>Sherertz RJ, Russell BA, Reuman PD (1984).
“Transmission of hepatitis A by transfusion of blood products.” </span></font><a
href="http://www.ncbi.nlm.nih.gov/pubmed/6087755"><font size=2 color=black
face=Times><span style='font-size:10.0pt;font-family:"Times","serif";
color:windowtext;text-decoration:none'>Arch Intern Med.</span></font></a><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>
144(8):1579-80.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>8.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></font></span></font><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>Leftwich
CI (1954). “Prevention of Infectious Hepatitis by Gamma Globulin.” Calif Med.
81(3): 226-229.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>9.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></font></span></font><font
size=2 face=Times><span style='font-size:10.0pt;font-family:"Times","serif"'>Delius
H, Gough NM, Cameron CH, Murray K (1983). “Structure of the hepatitis B
genome.” J Virol. 47(2): 337-343.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>10.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'>Wang GH, Seeger C (1992). “The reverse
transcriptase of hepatitis B virus acts as a protein primer for viral DNA
synthesis.” Cell; 71(4), 663-670.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>11.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'>Di Bisceglie, AM (2009). “Hepatitis B and
Hepatocellular Carcinoma.” Hepatology. 49(5 Suppl):S56-S60.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>12.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Han YF, Zhao J, Ma LY, Yin JG, Chang WJ,
Zhang HW, Cao GW (2011). “Factors predicting occurrence and prognosis of
hepatitis-B-virus-related hepatocellular carcinoma.” World J Gastroenterol.
17(38): 4258-4270.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>13.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Zuckerman AJ (1984). “Perinatal
transmission of hepatitis B.” Arch Dis Child. 59(11): 1007-1009.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>14.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Ishikawa T, Kakumu S, Yoshioka K, Yamada
M, Tanaka K, Higashi Y, Takayanagi M, Okumura A, Kojima A, Tamura T (1993)
“Relative immunogenicity of hepatitis B virus-encoded antigens as targets for
cytotoxic T-cell response.” Immunology; 80(2): 313-318.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><b><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif";font-weight:bold'>15.<font
size=1 face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font></b><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Iwarson S, Kjellman H, Ahlmen J, Ljunggren
C, Eriksson E, Selander D, Hermodsson S. (1975). “Hepatitis B immune serum
globulin and standard gamma globulin in prevention of hepatitis B infection
among hospital staff: a preliminary report.” Am J Med Sci; 270(2):385-9.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>16.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Takamizawa A, Mori C, Fuke I, Manabe S,
Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H (1991).
“Structure and Organization of the Hepatitis C Virus Genome Isolated from Human
Carriers.” Journal of Virology; 65(3): 1105-1113.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>17.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Cerny A, McHutchison JG, Pasquinelli C,
Brown ME, Brothers MA, Grabscheid B, Fowler P, Houghton M, Chisari FV (1995).
“Cytotoxic T lymphocyte response to hepatitis c virus-derived peptides
containing the HLA A2.1 binding motif.” J Clin Invest; 95(2): 521-530.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>18.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Gretch DR (1997). “Diagnostic tests for
hepatitis C.” Hepatology; 26(3 Suppl 1):43S-47S.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>19.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> McHutchison JG, Lawitz EJ, Shiffman ML, et
al. (2009) “interferon alfa-2b or alfa-2a with ribavirin for treatment of
hepatitis C infection.” N Engl J Med;361:580-593.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>20.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Wilby KJ, Partovi N, Ford JA, Greanya E,
Yoshida EM (2012). “Review of boceprevir and telaprevir for the treatment of
chronic hepatitis C.” Can J Gastroenterol; 26(4):205-10.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>21.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Rizzetto M, Canese MG, Gerin JL, London
WT, Sly DL, Purcell RH (1980). “Transmission of hepatitis B virus-associated
delta agent in chimpanzees.” J Infect Dis; 141:590-602.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>22.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Emerson, S. U., and R. H. Purcell (2003).
Hepatitis E virus. Rev. Med. Virol. 13:145-154.</span></font></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:11.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-11.0pt;
line-height:normal;text-autospace:none'><font size=2 face=Times><span
style='font-size:10.0pt;font-family:"Times","serif"'>23.<font size=1
face="Times New Roman"><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></font></span></font><font size=2 face=Times><span style='font-size:
10.0pt;font-family:"Times","serif"'> Reshetnyak VI, Karlovich TI, Ilchenko LU (2008).
Hepatitis G virus. World J Gastroenterol. 14(30): 4725-4734.</span></font></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><font size=2
face=Times><span style='font-size:10.0pt;line-height:115%;font-family:"Times","serif"'>&nbsp;</span></font></p>

<p class=MsoNormal><font size=2 face=Calibri><span style='font-size:11.0pt;
line-height:115%'>&nbsp;</span></font></p>

</div>

</body>

</html>
